For the roughly one-third of men with advanced prostate cancer who eventually exhaust every available androgen-targeting drug, the biology driving that final resistance has remained poorly understood. A mechanistic framework published in Nature Reviews Urology now maps how the very therapies designed to suppress androgen receptor signaling inadvertently ignite alternative oncogenic pathways — potentially explaining one of oncology's most stubborn clinical dead ends.
The analysis centers on a recently characterized resistance phenotype called double-null prostate cancer — tumors that have lost both androgen receptor (AR) expression and neuroendocrine differentiation markers. This subtype emerges specifically in patients treated with the potent agents abiraterone and enzalutamide. According to the review, androgen deprivation therapy (ADT) activates hepatocyte growth factor (HGF) signaling and the canonical WNT pathway. These cascades then drive two downstream processes: increased nuclear export of key regulatory molecules and accelerated ribosomal biogenesis. Together, these mechanisms are proposed to sustain tumor lineage plasticity — the capacity of cancer cells to reprogram their identity — enabling the emergence of heterogeneous castration-resistant phenotypes including the double-null state.
This mechanistic narrative carries significant translational weight. Lineage plasticity as a resistance engine has been gaining traction across multiple cancer types, and the identification of HGF and WNT as mediators in this context adds therapeutic specificity. Both pathways have existing drug candidates, and nuclear export inhibitors — such as selinexor — are already approved in other malignancies, suggesting combination strategies are plausible near-term targets. However, this is a review and mechanistic synthesis, not a clinical trial. The proposed pathways are under active investigation, and direct causal evidence in large human cohorts remains limited. The double-null phenotype itself is still being clinically characterized. While the framework is intellectually compelling, translating multi-pathway co-targeting into safe, effective regimens will require substantial further work. Still, for a disease state with virtually no good options, this represents a meaningful conceptual advance.